Immunosuppressants

Investigation Report on China's Lenalidomide Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 10, 2021
Chemicals, Plastics, Manufacturing, Drugs, Clinical medicine, Medicine, Immunosuppressants, Antineoplastic drugs, Aromatic amines, Phthalimides, Teratogens, Lenalidomide, Celgene, Immunomodulatory imide drug, Multiple myeloma

b'The "Investigation Report on China\'s Lenalidomide Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nLenalidomide is an oral immunomodulatory drug that is mainly used to treat blood cancers such as multiple myeloma, myelodysplastic syndrome, and lymphoma.

Key Points: 
  • b'The "Investigation Report on China\'s Lenalidomide Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nLenalidomide is an oral immunomodulatory drug that is mainly used to treat blood cancers such as multiple myeloma, myelodysplastic syndrome, and lymphoma.
  • Celgene\'s Lenalidomide, REVLIMID was launched in China in 2013.
  • In addition to Celgene, the other manufacturers in the Chinese Lenalidomide market are Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, and Beijing SL Pharmaceutical.\nSales revenue of Lenalidomide in the Chinese market has an increasing trend from 2016 to 2020.
  • Especially after Lenalidomide was included in the national medical insurance catalog in the second half of 2017, the annual growth rate in 2018 reached 547.4%.

Worldwide C5 Complement Inhibitors Drug Industry to 2026 - Detailed Profiles of Current Market Trends

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Health care, Pharmaceutical sciences, Orphan drugs, Eculizumab, Immunosuppressants, Medication, Pharmaceutical industry

b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insight on clinical and non-clinical factors that are driving the global C5 Complement Inhibitors market and its impact on the global pharmaceutical market landscape.

Key Points: 
  • b'DUBLIN, May 4, 2021 /PRNewswire/ -- The "Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insight on clinical and non-clinical factors that are driving the global C5 Complement Inhibitors market and its impact on the global pharmaceutical market landscape.
  • The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 3 commercially available C5 Complement Inhibitors with their regional level revenue, market share and the clinical profile.\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nGlobal pharmaceutical marketplace is undergoing subtle changes with respect to the need of the patient population.
  • In addition, the global sales of the C5 complement inhibitor drug market is growing at steadily, apparently depicting the increase in the consumption rate of the drugs by the patients.
  • Exclusive demand of the therapeutic approach such as C5 complement inhibitor therapy and the presence of few inhibitor drugs in the market is also predicted to align the entire market toward becoming more dynamic and drastic.

TFF Pharmaceuticals to Hold First Quarter 2021 Financial and Business Results Conference Call on May 13, 2021

Retrieved on: 
Tuesday, May 4, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, Drugs, Dosage forms, Astellas Pharma, Immunosuppressants, Macrolides, Tacrolimus, Powder, Health care, Health sciences, TFF Pharmaceuticals’ Thin Film Freezing technology platform, TFF Pharmaceuticals, TFF PHARMACEUTICALS’ THIN FILM FREEZING TECHNOLOGY PLATFORM, TFF PHARMACEUTICALS

The TFF process results in a \xe2\x80\x9cBrittle Matrix Particle,\xe2\x80\x9d which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue.

Key Points: 
  • The TFF process results in a \xe2\x80\x9cBrittle Matrix Particle,\xe2\x80\x9d which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue.
  • TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.
  • The TFF Platform is protected by 42 patents issued or pending in the US and internationally.
  • To learn more about TFF Pharmaceuticals and its product candidates, visit the Company\xe2\x80\x99s website at https://tffpharma.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005800/en/\n"

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

Retrieved on: 
Wednesday, April 28, 2021
Health sciences, Life sciences, Monoclonal antibodies, Immunosuppressants, Natalizumab, Biogen, Health care, Human polyomavirus 2, Therapy

In the U.S., TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of MS.

Key Points: 
  • In the U.S., TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of MS.
  • Risk factors that increase the risk of PML are the presence of anti-JC virus antibodies, prior immunosuppressant use and longer TYSABRI treatment duration.
  • Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.
  • These statements are based on our current beliefs and expectations and speak only as of the date of this news release.

Annual Report 2020 Active Biotech AB (publ)

Retrieved on: 
Thursday, April 22, 2021
Immunosuppressants, Laquinimod

+46 46 19 20 44, [email protected]\nThis information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act.

Key Points: 
  • +46 46 19 20 44, [email protected]\nThis information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act.
  • Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership.
  • Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a Phase I/II clinical program in patients with advanced solid tumors.
  • Laquinimod is advancing to phase II for treatment of non-infectious uveitis during second half of 2021.

Can-Fite Expands its Phase II COVID-19 Study to Europe

Retrieved on: 
Thursday, April 22, 2021
Health, Infectious diseases, Diabetes, Clinical trials, Pharmaceutical, Biotechnology, Monoclonal antibodies, Medical specialties, Organ systems, Immunosuppressants, Autoimmune diseases, Clinical medicine, Psoriasis, Itolizumab, Tildrakizumab, Piclidenoson, Can-Fite BioPharma Ltd., PICLIDENOSON, CAN-FITE BIOPHARMA LTD.

Patients are randomized in a 1:1 ratio to receive 2 mg Piclidenoson twice daily or placebo, and treated for up to 28 days.

Key Points: 
  • Patients are randomized in a 1:1 ratio to receive 2 mg Piclidenoson twice daily or placebo, and treated for up to 28 days.
  • Safety and pharmacokinetic data will also be captured.\nPiclidenoson\xe2\x80\x99s robust anti-inflammatory effect has the potential to treat COVID-19 and its mutations because it treats disease manifestations.
  • The drug has anti-inflammatory effects proven in Phase II psoriasis clinical studies and in an interim analysis of an ongoing Phase III psoriasis study.
  • The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19.

Can-Fite Initiates Preclinical Studies Required by FDA and EMA for the Registration of its Two Lead Drug Candidates

Retrieved on: 
Tuesday, April 20, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Drugs, Health care, Immunosuppressants, Food and Drug Administration, Monoclonal antibodies, TNF inhibitors, Arthritis, Fast track, Psoriasis, Briakinumab, Janus kinase inhibitor

Namodenoson has Orphan Drug Status in the U.S. and Europe and Fast Track Status with the FDA.

Key Points: 
  • Namodenoson has Orphan Drug Status in the U.S. and Europe and Fast Track Status with the FDA.
  • The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis.
  • These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
  • Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.

Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

Retrieved on: 
Thursday, April 15, 2021
Biotechnology, Pharmaceutical, Health, Medical Supplies, Immunosuppressants, Peptides, Voclosporin, Aurinia

b'Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET.\nIn order to participate in the audio webcast, interested parties can access the live webcast under "News/Events\xe2\x80\x9d through the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the Aurinia corporate website at www.auriniapharma.com .

Key Points: 
  • b'Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 2:30 p.m. ET.\nIn order to participate in the audio webcast, interested parties can access the live webcast under "News/Events\xe2\x80\x9d through the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the Aurinia corporate website at www.auriniapharma.com .
  • A replay of the webcast will be available on Aurinia\xe2\x80\x99s website.\nAurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need.
  • The Company has introduced LUPKYNIS\xe2\x84\xa2 (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN).
  • The Company\xe2\x80\x99s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005158/en/\n'

Additional support for Ontario to fight the COVID-19 outbreak

Retrieved on: 
Sunday, April 18, 2021
Immunosuppressants, Tocilizumab, ONTARIO, Health care, Clinical medicine, Medicine

These sites have already helped 3,900 Ontarians isolate safely to prevent the spread of the virus.\nSigninga bilateral agreement between the Government of Canada and theGovernment of Ontario to enhance virtual health services in the province.

Key Points: 
  • These sites have already helped 3,900 Ontarians isolate safely to prevent the spread of the virus.\nSigninga bilateral agreement between the Government of Canada and theGovernment of Ontario to enhance virtual health services in the province.
  • This agreement comes with $46 million in funding to expand Ontario\'s efforts on virtual health care during the pandemic.\nProviding an additional supply of tocilizumab and other needed drugs for Ontario through reallocation from other provinces and territories.
  • These MHUwere approved in January and are currently deployed inToronto and Hamilton.
  • We are committed to taking a Team Canada approach to beating this virus and keeping Canadians safe, healthy,and supported.

Global C5 Complement Inhibitor Soliris Ultomiris Market Clinical Trial Research Outlook 2026

Retrieved on: 
Sunday, April 18, 2021
Orphan drugs, Drugs, Immunosuppressants, Eculizumab, Health care, Ravulizumab, C5, Protein kinase inhibitors, Medicinal chemistry

b'"Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nThe C5 complement inhibitors are emerging as a novel therapeutic approach for the management of rare disease and this segment is expected to hold a major share in the future orphan drug market.

Key Points: 
  • b'"Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nThe C5 complement inhibitors are emerging as a novel therapeutic approach for the management of rare disease and this segment is expected to hold a major share in the future orphan drug market.
  • Various new C5 complement targeting candidates are under clinical stage of development, which will further broaden the therapeutic potential of this segment and takes C5 complement inhibitor market to the next level.
  • Therefore, C5 complement market has potential to transform the future market of rare diseases and intense growth is expected in this sector.
  • It is believed that the C5 complement inhibitors will overtake a major portion of the orphan drugs segment in near future.\n'